A Study To Assess The Effect Of Linezolid On QTc Interval
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The FDA has asked Pfizer to assess the risk of linezolid on QT interval (obtained from ECG
readings) which could predispose patients to ventricular arrhythmias. This study is conducted
to satisfy this requirement.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fluoroquinolones Linezolid Moxifloxacin Norgestimate, ethinyl estradiol drug combination